title: BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.
abstract: Germline mutations of the tumour suppressor gene BRCA1 are involved in the predisposition and development of breast cancer and account for 20-45% of all hereditary cases. There is an increasing evidence that these tumours are characterised by a specific phenotype and pattern of gene expression. We have hypothesised that differences in chemosensitivity might parallel molecular heterogeneity of hereditary and sporadic breast tumours. To this end, we have investigated the chemosensitivity of the BRCA1-defective HCC1937 breast cancer cell line, and the BRCA1-competent MCF-7 (hormone-sensitive) and MDA-MB231 (hormone-insensitive) breast cancer cell lines using the MTT assay. The 50% inhibitory concentration (IC(50)) for the individual compounds were derived by interpolate plot analysis of the logarithmic scalar concentration curve after a 48 h exposure. HCC1937 cells were significantly (P<0.005) more sensitive to cisplatin (CDDP) (IC(50) : 30-40 microM) compared with MCF-7 (IC(50) : 60-70 microM) and MDA-MB231 (IC(50) : 90-100 microM) cells. On the other hand, BRCA1-defective breast cancer cells were significantly less sensitive to doxorubicin (Dox) (IC(50) : 45-50 microM) compared with MCF-7 (IC(50) : 1-5 microM) and MDA-MB231 (IC(50) : 5-10 microM) (P<0.02), as well as to paclitaxel (Tax) (IC(50) : >2 microM for HCC1937, 0.1-0.2 microM for MCF-7 and 0.01-0.02 microM for MDA-MB231) (P<0.001). Full-length BRCA1 cDNA transfection of BRCA1-defective HCC1937 cells led to the reconstituted expression of BRCA1 protein in HCC1937/(WT)BRCA1-derived cell clone, but did not reduce tumour cell growth in soft agar. BRCA1 reconstitution reverted the hypersensitivity to CDDP (P<0.02), and restored the sensitivity to Dox (P<0.05) and Tax (P<0.001), compared with parental HCC1937 cells. Taken together, our findings suggest a specific chemosensitivity profile of BRCA1-defective cells in vitro, which is dependent on BRCA1 protein expression, and suggest prospective preclinical and clinical investigation for the development of tailored therapeutical approaches in this setting.
authors.affiliation: Department of Experimental and Clincal Medicine, 'Magna Graecia' University, Italy. tassone@unicz.it
authors.forename: P
authors.initials: P
authors.lastname: Tassone
authors.forename: P
authors.initials: P
authors.lastname: Tagliaferri
authors.forename: A
authors.initials: A
authors.lastname: Perricelli
authors.forename: S
authors.initials: S
authors.lastname: Blotta
authors.forename: B
authors.initials: B
authors.lastname: Quaresima
authors.forename: M L
authors.initials: ML
authors.lastname: Martelli
authors.forename: A
authors.initials: A
authors.lastname: Goel
authors.forename: V
authors.initials: V
authors.lastname: Barbieri
authors.forename: F
authors.initials: F
authors.lastname: Costanzo
authors.forename: C R
authors.initials: CR
authors.lastname: Boland
authors.forename: S
authors.initials: S
authors.lastname: Venuta
mesh_terms: D000970:Antineoplastic Agents / Q000633:toxicity*; D017209:Apoptosis / Q000187:drug effects; D019313:BRCA1 Protein / Q000172:deficiency* / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000633:toxicity; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000633:toxicity
chemical_list: D000970:Antineoplastic Agents; D019313:BRCA1 Protein; D017239:Paclitaxel; D002945:Cisplatin